Heidi Savage

2.3k total citations
23 papers, 1.4k citations indexed

About

Heidi Savage is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Heidi Savage has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Heidi Savage's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Advanced Breast Cancer Therapies (6 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Heidi Savage is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Advanced Breast Cancer Therapies (6 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Heidi Savage collaborates with scholars based in United States, Spain and France. Heidi Savage's co-authors include Mark R. Lackner, Lukas C. Amler, Elizabeth A. Punnoose, Carol O’Brien, Jill M. Spoerke, Leanne Berry, Lori S. Friedman, Marcia Belvin, Timothy R. Wilson and Guy Cavet and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Heidi Savage

22 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heidi Savage United States	12	801	731	489	389	138	23	1.4k
Ariella B. Hanker United States	15	942 1.2×	759 1.0×	453 0.9×	445 1.1×	131 0.9×	41	1.6k
Estela Pineda Spain	16	624 0.8×	669 0.9×	692 1.4×	354 0.9×	271 2.0×	65	1.6k
Robert Lemos United States	15	878 1.1×	438 0.6×	531 1.1×	207 0.5×	99 0.7×	20	1.4k
Katherine E. Hutchinson United States	19	972 1.2×	920 1.3×	595 1.2×	536 1.4×	180 1.3×	48	1.8k
Selma Pennacchietti Italy	10	1.1k 1.4×	565 0.8×	661 1.4×	344 0.9×	74 0.5×	11	1.9k
Umesh Bhanot United States	18	1.0k 1.3×	704 1.0×	678 1.4×	499 1.3×	84 0.6×	44	1.9k
Pramudita R. Prasetyanti Netherlands	13	906 1.1×	951 1.3×	504 1.0×	186 0.5×	51 0.4×	14	1.6k
Karen G. Montgomery Australia	15	1.1k 1.4×	528 0.7×	362 0.7×	397 1.0×	188 1.4×	17	1.6k
Dustin A. Deming United States	24	616 0.8×	1.0k 1.4×	455 0.9×	327 0.8×	91 0.7×	157	1.8k
Hans Kristian Moen Vollan Norway	18	705 0.9×	466 0.6×	573 1.2×	213 0.5×	51 0.4×	25	1.3k

Countries citing papers authored by Heidi Savage

Since Specialization

Citations

This map shows the geographic impact of Heidi Savage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Savage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Savage more than expected).

Fields of papers citing papers by Heidi Savage

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Savage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Savage. The network helps show where Heidi Savage may publish in the future.

Co-authorship network of co-authors of Heidi Savage

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi Savage. A scholar is included among the top collaborators of Heidi Savage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi Savage. Heidi Savage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lusk, Anne, et al.. (2024). Rethinking the Design of Bikes and Bike Networks for Seniors: Sustainability, Climate Change, Alzheimer’s Disease, and Caregivers. Sustainability. 16(23). 10340–10340. 1 indexed citations

Chen, Jessica W., William Jacot, Javier Cortés, et al.. (2023). ER +, HER2 − advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Molecular Oncology. 17(10). 2000–2016. 1 indexed citations

Hutchinson, Katherine E., Jessica W. Chen, Heidi Savage, et al.. (2023). Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers. Genome Medicine. 15(1). 28–28. 14 indexed citations

Chen, Jessica W., Karthikeyan Murugesan, Justin Y. Newberg, et al.. (2022). Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. JCO Precision Oncology. 6(6). e2200341–e2200341. 9 indexed citations

Oliveira, Mafalda, Aditya Bardia, Sung‐Bae Kim, et al.. (2022). Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC). Cancer Research. 82(4_Supplement). P5–16. 2 indexed citations

Savage, Heidi, Mafalda Oliveira, Carlos H. Barrios, et al.. (2021). Abstract PS5-06: Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial. Cancer Research. 81(4_Supplement). PS5–6.

Moore, Heather M., Heidi Savage, Carol O’Brien, et al.. (2019). Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. Molecular Cancer Therapeutics. 19(1). 292–303. 8 indexed citations

Wilson, Timothy R., Akshata R. Udyavar, Ching‐Wei Chang, et al.. (2018). Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. Molecular Cancer Research. 17(1). 97–108. 15 indexed citations

Ignatiadis, Michail, Gert Van den Eynden, Marco Fornili, et al.. (2018). Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. JNCI Journal of the National Cancer Institute. 111(1). 69–77. 58 indexed citations

10.

Juric, Dejan, Ian E. Krop, Ramesh K. Ramanathan, et al.. (2017). Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discovery. 7(7). 704–715. 120 indexed citations

11.

Savage, Heidi, Carol O’Brien, Heather M. Moore, et al.. (2016). Abstract 372: Taselisib enhances the potency of ERBB inhibitors in biomarker-defined subsets of head and neck squamous carcinoma cell lines. Cancer Research. 76(14_Supplement). 372–372. 1 indexed citations

12.

Wilson, Timothy R., Jianjun Yu, Xuyang Lu, et al.. (2016). The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. npj Breast Cancer. 2(1). 16022–16022. 25 indexed citations

13.

Spoerke, Jill M., Steven Gendreau, Kimberly Walter, et al.. (2016). Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nature Communications. 7(1). 11579–11579. 219 indexed citations

14.

Hoeflich, Klaus P., Jane Guan, Kyle A. Edgar, et al.. (2016). The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. Genes & Cancer. 7(3-4). 73–85. 15 indexed citations

15.

O’Shaughnessy, Joyce, Timothy R. Wilson, Maren K. Levin, et al.. (2014). Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy.. Journal of Clinical Oncology. 32(15_suppl). 582–582. 1 indexed citations

16.

O’Brien, Carol, Jeffrey J. Wallin, Deepak Sampath, et al.. (2010). Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models. Clinical Cancer Research. 16(14). 3670–3683. 201 indexed citations

17.

Punnoose, Elizabeth A., Siminder Atwal, Jill M. Spoerke, et al.. (2010). Molecular Biomarker Analyses Using Circulating Tumor Cells. PLoS ONE. 5(9). e12517–e12517. 238 indexed citations

18.

Hoeflich, Klaus P., Carol O’Brien, Zachary Boyd, et al.. (2009). In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. Clinical Cancer Research. 15(14). 4649–4664. 385 indexed citations

19.

Zha, Jiping, Carol O’Brien, Heidi Savage, et al.. (2009). Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Molecular Cancer Therapeutics. 8(8). 2110–2121. 66 indexed citations

20.

Boyd, Zachary, Qun Wu, Carol O’Brien, et al.. (2008). Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Molecular Cancer Therapeutics. 7(12). 3695–3706. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact